全球癌症标靶阿尔法疗法市场

本研究报告概况了癌症治疗的标靶阿尔法疗法的全球市场并分析了市场趋势。

基准年数据包括 2024 年全球收益（百万美元）、2025 年估计数据以及到 2030 年的估计和预测复合年增长率。

调查范围

本报告概述并分析了全球癌症标靶α疗法 (TAT) 市场。报告包含基准年2024年的全球收益（百万美元）以及预测期2025年至2030年的估值。市场按癌症类型细分。

本报告重点关注影响市场和供应商格局的趋势和挑战。报告分析了各公司的环境、社会和管治(ESG) 发展情况，并探讨了与市场相关的新兴技术。此外，报告还包含竞争和产品线分析。公司简介部分涵盖关键财务资讯、产品系列以及行业领导者的最新发展动态。

报告内容

• 全球癌症标靶阿尔法疗法（TAT）市场概况及分析
• 全球市场趋势分析，包括 2022 年至 2024 年的历史市场收益数据、2025 年的估计和预测以及 2030 年的复合年增长率预测
• 该报告估计了全球市场的当前市场规模和收益预测，并提供了按癌症类型和地区分類的市场份额分析。
• 有关市场动态、技术进步、法规、预测和宏观经济变数影响的事实和数据
• 波特五力模型的见解、新兴趋势和技术资讯、最新发展以及产品平臺分析
• 永续性趋势和 ESG 发展概述，重点在于消费者态度、ESG 风险评估和主要企业的实践
• 专利分析，包括主要授权和公布的专利
• 产业结构分析，包括公司市场份额和排名、策略倡议、併购活动和创业融资前景
• 主要企业简介

目录

第一章执行摘要

第二章 市场概况

• 概述
• 宏观经济因素分析
• 人口因素
• 地缘政治因素
• 美国关税法的影响
• 波特五力分析
• 价值链分析

第三章 市场动态

• 市场动态
• 市场驱动因素
• 癌症发生率上升
• 精准医疗的需求
• 肿瘤学中未满足的治疗需求
• 加强策略性倡议
• 市场限制
• 供应炼和製造问题
• 监管障碍
• 市场挑战
• 剂量计算
• 后座力效应
• 市场机会
• 新目标
• 联合治疗

第四章：监理现状

• 监管情景
• 美国
• 欧洲联盟
• 日本

第五章 新兴科技与发展

• 新兴技术
• 药物发行策略的进展
• 治疗诊断学
• 管道分析
• 关键要点

第六章市场区隔分析

• 概述
• 细分市场
• 按癌症类型进行市场分析
• 关键要点
• 摄护腺癌
• 神经内分泌肿瘤
• 其他的
• 按地区细分
• 区域市场分析
• 关键要点
• 北美洲
• 欧洲
• 亚太地区
• 其他地区

第七章 竞争讯息

• 关键要点
• 市场分析
• 策略倡议
• 合约、合作和伙伴关係
• 获得
• 其他策略

第八章 癌症治疗市场中标靶阿尔法疗法的永续性：ESG 视角

第九章 附录

• 调查方法
• 来源
• 简称
• 公司简介
• ACTINIUM PHARMACEUTICALS INC.
• ADVANCELL PTY LTD.
• BAYER AG
• CONVERGENT THERAPEUTICS INC.
• FUSION PHARM
• NOVARTIS AG
• ORANO MED
• PERSPECTIVE THERAPEUTICS
• RADIOMEDIX INC.
• RAYZEBIO INC.
• 市场上的新兴新Start-Ups

This report provides an overview of the global market for targeted alpha therapies for cancer and analyzes market trends. It includes global revenue ($ millions) for the base year data 2024 and estimated data for 2025, forecasted CAGRs through 2030.

Report Scope

The report provides an overview of the global market for targeted alpha therapies (TAT) for cancer and analyzes market trends. It includes global revenue ($ million) for the base year data 2024 and estimated data for the forecast period 2025 through 2030. The market is segmented based on cancer type.

The report focuses on trends and challenges that affect the market and vendor landscape. It analyzes corporate environmental, social and governance (ESG) developments and discusses emerging technologies related to the market. The report includes an analysis of the competitive landscape and pipeline analysis. A section dedicated to company profiles addresses key financials, product portfolios and recent developments involving industry leaders.

Report Includes

• Overview and an analysis of the global market for targeted alpha therapies (TAT) for cancer treatment
• Analyses of the global market trends, with historical market revenue data from 2022 to 2024, estimates for 2025, and projections of CAGRs through 2030
• Estimates of the current market size and revenue prospects of the global market, accompanied by a market share analysis by cancer type and region
• Facts and figures pertaining to market dynamics, technological advances, regulations, prospects and the impacts of macroeconomic variables
• Insights derived from Porter's Five Forces model, and information on emerging trends and technologies, latest developments, and product pipeline analysis
• Overview of sustainability trends and ESG developments, with emphasis on consumer attitudes, as well as the ESG risk ratings and practices of leading companies
• A relevant patent analysis, featuring key granted and published patents
• Analysis of the industry structure, including companies' market shares and rankings, strategic initiatives, M&A activity and a venture funding outlook
• Profiles of the leading companies

Table of Contents

Chapter 1 Executive Summary

• Market Outlook
• Scope of Report
• Market Summary
• Overview
• Current Market Scenario
• Segmental Analysis
• Emerging Technologies
• Conclusion

Chapter 2 Market Overview

• Overview
• Macroeconomic Factors Analysis
• Demographic Factors
• Geopolitical Factors
• Impact of the U.S. Tariff Laws
• Porter's Five Forces Analysis
• Potential of New Entrants: Moderate to Low
• Bargaining Power of Suppliers: High
• Bargaining Power of Buyers: Moderate
• Threat of Substitute Products or Services: Moderate
• Industry Competition: Low
• Value Chain Analysis

Chapter 3 Market Dynamics

• Market Dynamics
• Market Drivers
• Increased Prevalence of Cancer
• Demand for Precision Medicine
• Unmet Treatment Need in Oncology
• Increased Strategic Initiatives
• Market Restraints
• Supply Chain and Manufacturing Issues
• Regulatory Hurdles
• Market Challenges
• Dosimetry Calculations
• Recoil Effect
• Market Opportunities
• New Targets
• Combination Therapies

Chapter 4 Regulatory Landscape

• Regulatory Scenario
• The U.S.
• European Union
• Japan

Chapter 5 Emerging Technologiesand Developments

• Emerging Technologies
• Advances in Drug Delivery Strategies
• Theranostics
• Pipeline Analysis
• Key Takeaways

Chapter 6 Market Segmentation Analysis

• Overview
• Segmentation Breakdown
• Market Analysis by Cancer Type
• Key Takeaways
• Prostate Cancer
• Neuroendocrine Tumors
• Other Cancers
• Geographic Breakdown
• Market Analysis by Region
• Key Takeaways
• North America
• Europe
• Asia-Pacific
• Rest of the World

Chapter 7 Competitive Intelligence

• Key Takeaways
• Market Analysis
• Strategic Initiatives
• Agreements, Collaborations and Partnerships
• Acquisitions
• Other Strategies

Chapter 8 Sustainability in Targeted Alpha Therapies for Cancer Treatment Market: An ESG Perspective

• Introduction to ESG
• Sustainability in the Targeted Alpha Therapies Industry
• ESG Performance Analysis
• Environmental Initiatives
• Social Initiatives
• Governance Initiatives
• ESG Risk Ratings
• Conclusion

Chapter 9 Appendix

• Research Methodology
• Sources
• Abbreviations
• Company Profiles
• ACTINIUM PHARMACEUTICALS INC.
• ADVANCELL PTY LTD.
• BAYER AG
• CONVERGENT THERAPEUTICS INC.
• FUSION PHARM
• NOVARTIS AG
• ORANO MED
• PERSPECTIVE THERAPEUTICS
• RADIOMEDIX INC.
• RAYZEBIO INC.
• Emerging Startups in the Market

List of Tables

• Summary Table : Global Market for Targeted Alpha Therapies for Cancer Treatment, by Cancer Type, Through 2030
• Table 1 : Common Characteristics, Production Methods, Delivery Strategies and Clinical Applications of Alpha-Emitters
• Table 2 : Global Cancer Incidence and Mortality Rates, by the WHO Region, 2022
• Table 3 : Strategic Initiatives in Targeted Alpha Therapy Market, 2023-2025
• Table 4 : List of Selected Targeted Alpha Therapies, July 2025
• Table 5 : Global Market for Targeted Alpha Therapies for Cancer Treatment, by Cancer Type, Through 2030
• Table 6 : Agreements, Collaborations and Partnerships in the Targeted Alpha Therapies for Cancer Treatment Market, 2021-2025
• Table 7 : Acquisitions in the Targeted Alpha Therapies for Cancer Treatment Market, 2021-2024
• Table 8 : Other Strategic Initiatives in the Targeted Alpha Therapies for Cancer Treatment Market, 2022-2025
• Table 9 : ESG Risk Rankings for Targeted Alpha Therapies Companies, 2025*
• Table 10 : Information Sources in this Report
• Table 11 : Abbreviations
• Table 12 : Actinium Pharmaceuticals Inc.: Company Snapshot
• Table 13 : Actinium Pharmaceuticals Inc.: Financial Performance, FY 2023 and 2024
• Table 14 : Actinium Pharmaceuticals Inc.: Product Pipeline
• Table 15 : Actinium Pharmaceuticals Inc.: News/Key Developments, 2023-2025
• Table 16 : AdvanCell Pty Ltd.: Company Snapshot
• Table 17 : AdvanCell Pty Ltd.: Product Pipeline
• Table 18 : AdvanCell Pty Ltd.: News/Key Developments, 2023-2025
• Table 19 : Bayer AG: Company Snapshot
• Table 20 : Bayer AG: Financial Performance, FY 2023 and 2024
• Table 21 : Bayer AG: Product Portfolio
• Table 22 : Bayer AG: News/Key Developments, 2021-2025
• Table 23 : Convergent Therapeutics Inc.: Company Snapshot
• Table 24 : Convergent Therapeutics Inc.: Product Pipeline
• Table 25 : Convergent Therapeutics Inc.: News/Key Developments, 2021-2024
• Table 26 : Fusion Pharma: Company Snapshot
• Table 27 : Fusion Pharma: Product Pipeline
• Table 28 : Fusion Pharma: News/Key Developments, 2024
• Table 29 : Novartis AG: Company Snapshot
• Table 30 : Novartis AG: Financial Performance, FY 2023 and 2024
• Table 31 : Novartis AG: Product Pipeline
• Table 32 : Novartis AG: News/Key Developments, 2024
• Table 33 : Orano Med: Company Snapshot
• Table 34 : Orano Med: Product Pipeline
• Table 35 : Orano Med: News/Key Developments, 2023-2025
• Table 36 : Perspective Therapeutics: Company Snapshot
• Table 37 : Perspective Therapeutics: Financial Performance, FY 2023 and 2024
• Table 38 : Perspective Therapeutics: Product Pipeline
• Table 39 : Perspective Therapeutics: News/Key Developments, 2024
• Table 40 : RadioMedix Inc.: Company Snapshot
• Table 41 : RadioMedix Inc.: Product Pipeline
• Table 42 : RadioMedix Inc.: News/Key Developments, 2022-2025
• Table 43 : RayzeBio Inc.: Company Snapshot
• Table 44 : RayzeBio Inc.: Product Pipeline
• Table 45 : RayzeBio Inc: News/Key Developments, 2024
• Table 46 : Other Emerging Startups in the Targeted Alpha Therapies for Oncology Market

List of Figures

• Summary Figure : Global Market Shares of Targeted Alpha Therapies for Cancer Treatment, by Cancer Type, 2030
• Figure 1 : Porter's Five Forces Analysis of the Targeted Alpha Therapies for Cancer Treatment Market
• Figure 2 : Targeted Alpha Therapies for Cancer: Value Chain Analysis
• Figure 3 : Market Dynamics of Targeted Alpha Therapies for Cancer Treatment
• Figure 4 : Cancer Incidence in the U.S., 2010-2022
• Figure 5 : Clinical Trials Shares on Targeted Alpha Therapies, by Phase, as of July 2025
• Figure 6 : Clinical Trials Shares on Targeted Alpha Therapies, by Study Type, July 2025
• Figure 7 : Clinical Trials Shares on Targeted Alpha Therapies, by Study Status, as of July 2025
• Figure 8 : Clinical Trials Shares on Targeted Alpha Therapies, by Radioisotope, as of July 2025
• Figure 9 : Bayer AG: Revenue Shares, by Business Unit, FY 2024
• Figure 10 : Bayer AG: Revenue Shares, by Country/Region, FY 2024
• Figure 11 : Novartis AG: Revenue Shares, by Business Unit, FY 2024
• Figure 12 : Novartis AG: Revenue Shares, by Country/Region, FY 2024